CytomX Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
CytomX Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2014 to Q3 2024.
  • CytomX Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $4.11M, a 31.6% increase year-over-year.
  • CytomX Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $6.71M.
  • CytomX Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$6.48M, a 93.6% increase from 2022.
  • CytomX Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$101M, a 12.7% increase from 2021.
  • CytomX Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$116M, a 44.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $6.71M $4.11M +$988K +31.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $5.72M -$8.45M -$5.1M -152% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $10.8M $11.7M +$17.3M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$6.48M -$606K +$8.9M +93.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$15.4M $3.12M +$32.8M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$48.2M -$3.35M +$26.7M +88.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$74.9M -$5.65M +$26.4M +82.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$101M -$9.51M +$25.4M +72.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$127M -$29.7M +$1.33M +4.28% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$128M -$30.1M -$3.36M -12.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$125M -$32.1M -$8.66M -37% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$116M -$34.9M -$10.8M -45% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-03-27
Q3 2021 -$105M -$31M -$5.82M -23.1% Jul 1, 2021 Sep 30, 2021 10-K/A 2023-03-27
Q2 2021 -$99.4M -$26.7M -$940K -3.65% Apr 1, 2021 Jun 30, 2021 10-K/A 2023-03-27
Q1 2021 -$98.5M -$23.4M -$17.9M -326% Jan 1, 2021 Mar 31, 2021 10-K/A 2023-03-27
Q4 2020 -$80.5M -$24.1M +$43.9M +64.6% Oct 1, 2020 Dec 31, 2020 10-K/A 2023-03-27
Q3 2020 -$124M -$25.2M +$501K +1.95% Jul 1, 2020 Sep 30, 2020 10-K/A 2023-03-27
Q2 2020 -$125M -$25.8M +$5.48M +17.5% Apr 1, 2020 Jun 30, 2020 10-K/A 2023-03-27
Q1 2020 -$130M -$5.49M +$11.1M +66.9% Jan 1, 2020 Mar 31, 2020 10-K/A 2023-03-27
Q4 2019 -$141M -$68M -$42.2M -163% Oct 1, 2019 Dec 31, 2019 10-K/A 2023-03-27
Q3 2019 -$99.3M -$25.7M -$2.54M -11% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$96.8M -$31.2M -$18M -136% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$78.8M -$16.6M -$935K -5.98% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$77.9M -$25.8M -$24.6M -1970% Oct 1, 2018 Dec 31, 2018 10-K 2019-02-27
Q3 2018 -$53.3M -$23.2M -$12.2M -110% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$41.2M -$13.3M +$12.1M +47.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$53.3M -$15.6M -$7.02M -81.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$46.3M -$1.25M +$13M +91.2% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 -$59.2M -$11M +$3.89M +26.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$63.1M -$25.4M -$11.1M -78% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$52M -$8.61M +$7.57M +46.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$59.6M -$14.2M -$2.71M -23.5% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 -$56.9M -$14.9M -$3.65M -32.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 -$53.2M -$14.3M -$8.72M -157% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 -$44.5M -$16.2M -$11.3M -232% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q4 2015 -$33.2M -$11.5M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-07
Q3 2015 -$11.3M -$7.81M -225% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 -$5.54M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-03
Q1 2015 -$4.87M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-06
Q3 2014 -$3.46M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.